Stock Events

Stock Events

United Therapeutics 

€477.3
157
+€0+0% Today

Statistics

Day High
477.3
Day Low
477.3
52W High
506
52W Low
240.7
Volume
30
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5AugExpected
Q4 2025
Q1 2026
Next
4.97
5.48
6
6.52
Expected EPS
6.18267656777
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow UTH.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
GSK
GSK
Mkt Cap103.01B
GlaxoSmithKline competes in the pulmonary arterial hypertension (PAH) space, a key area for United Therapeutics.
Johnson & Johnson
JNJ
Mkt Cap546.9B
Johnson & Johnson, through its subsidiary Actelion, offers products that directly compete in the PAH market.
Pfizer
PFE
Mkt Cap149.77B
Pfizer has therapies for cardiovascular diseases, including PAH, making it a competitor.
Bristol-Myers Squibb
BMY
Mkt Cap118.87B
Bristol Myers Squibb competes in various therapeutic areas with United Therapeutics, including cardiovascular diseases.
Novartis
NVS
Mkt Cap279.67B
Novartis provides treatments for PAH, directly competing with United Therapeutics' portfolio.
Abbvie
ABBV
Mkt Cap365.43B
AbbVie, through its broad range of pharmaceutical products, competes in areas that overlap with United Therapeutics' interests.
Merck
MRK
Mkt Cap277.02B
Merck & Co. has a diverse pharmaceutical portfolio that includes treatments for conditions in competitive areas with United Therapeutics.
Lilly(Eli) &
LLY
Mkt Cap862.01B
Eli Lilly competes in the broader pharmaceutical market, including treatments for conditions that overlap with United Therapeutics' focus areas.
AMGEN
AMGN
Mkt Cap178B
Amgen's portfolio includes therapies for cardiovascular diseases, making it a competitor in some of United Therapeutics' markets.
Biogen
BIIB
Mkt Cap27.62B
Biogen, while primarily focused on neurological disorders, has ventured into areas that could compete with United Therapeutics' treatments.

About

There is no Profile data available for UTH.MU.
Show more...
CEO
Country
United States
ISIN
US91307C1027

Listings

STU
DE
UTH.STU
MU
DE
UTH.MU
XNAS
US
UTHR
F
DE
UTH.F

0 Comments

Share your thoughts

FAQ

What is United Therapeutics stock price today?▼
The current price of UTH.MU is €477.3 EUR — it has increased by +0% in the past 24 hours. Watch United Therapeutics stock price performance more closely on the chart.
What is United Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange United Therapeutics stocks are traded under the ticker UTH.MU.
Is United Therapeutics stock price growing?▼
UTH.MU stock has fallen by -2.09% compared to the previous week, the month change is a -1.98% fall, over the last year United Therapeutics has showed a +83.37% increase.
When is the next United Therapeutics earnings date?▼
United Therapeutics is going to release the next earnings report on August 05, 2026.
What were United Therapeutics earnings last quarter?▼
UTH.MU earnings for the last quarter are 4.97 EUR per share, whereas the estimation was 5.97 EUR resulting in a -16.83% surprise. The estimated earnings for the next quarter are N/A EUR per share.
In which sector is United Therapeutics located?▼
United Therapeutics operates in the Materials sector.
When did United Therapeutics complete a stock split?▼
United Therapeutics has not had any recent stock splits.